EBDLR v2.0 – it is lightweight, portable, and budget-friendly solution
to fight acute liver failure.
Acute Liver Failure (ALF) is a life-threatening illness with a high mortality rate of up to 50-75%. It can progress rapidly, with liver failure developing within days to weeks after the onset of symptoms, without any prior existing liver disease.
Acute-on-Chronic Liver Failure (ACLF) is a serious and life-threatening condition that occurs in people who already have chronic liver disease. It develops suddenly, often triggered by infections, alcohol use, or other stressors on the liver. ACLF can worsen quickly over days to weeks and is associated with a high risk of death, with a one-year mortality rate of around 40–50%.
Unfortunately, liver transplant surgery is currently the only available treatment, but it's expensive and constrained by limited organ availability.
KNOW MORE
The EBDLR v2.0 is a state-of-the-art device built specifically to supplement the liver and enable it to regenerate itself with the support of the device.
KNOW MOREThe Pre-clinical studies have demonstrated promising results in rescuing subjects with ALF.
KNOW MOREYkrita Lifesciences has filed three patents for the EBDLR System in India, the PCT, and the USPTO, emphasizing the device's innovative nature and potential life-saving impact.
KNOW MORE
CEO and Director- Clinical & Biological Sciences
Advisor- Engineering and Design
Director Commercial, Legal and Administration
Chief Quality Officer
Project Head - Clinical Research & Development
Project Head - Engineering & Development
Fabrication Engineer
Industrial Designer
Embedded Engineer
Biomedical Engineer
QA/RA Executive
Senior Research Executive
Senior Research Executive
Senior Research Executive
Senior Research Executive
Senior Research Executive
Junior Research Executive
Junior Research Executive
Senior Executive - Finance & Accounting
Office & Accounting Executive
Administrative Executive